Recipharm, a contract development and manufacturing organization (CDMO), announced the completion of a complex serialization project for Korea for one of its leading customers; Abbott. The initiative commenced in April 2014.
The CDMO met the precise customer and market requirement to produce a datamatrix code, including serial number, with full compliance with complex regulations, similar to foreseen European Union rules. Recipharm helped Abbott achieve full compliance with country-specific regulations, to a blister packaging line; with the need differing markedly from Chinese serialization. Validation batches planned to be shipped to Korea mid-March 2015.
From the outset, integration formed a key tenet with the establishment of joint company strategic teams and the sharing of critical information. Costs were kept to a minimum and full implementation achieved.
Stephane Guisado, General Manager at Recipharm in Fontaine said, “We are delighted with the success of this serialization project for the Korean market carried out for Abbott, a long-standing pharmaceutical partner of ours. In this case, it ensured that our customer complied in full with the relevant serialization regulations set down by Korea. We were pleased to have received such strong thanks and recognition from the Abbott project team for the work that we staged on this project. We look forward to rolling out further projects during 2015.”
Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. The company manufactures more than 400 different products to customers ranging from “big pharma” to smaller R&D companies.
